Search research articles
Contact Us
Filters
Showing results (1-10 of 40) with videos related to
Page
of 4
Sort By:
The Oncologist
|
November 11, 2018
"As Long as You Ask": A Qualitative Study of Biobanking Consent-Oncology Patients' and Health Care Professionals' Attitudes, Motivations, and Experiences-the B-PPAE Study
Sonia Yip, Jennifer Fleming, Heather L Shepherd, et al.
British Journal of Cancer
|
August 6, 2019
Challenges of international oncology trial collaboration-a call to action
Monica Tang, Heikki Joensuu, Robert J Simes, et al.
Gynecologic Oncology
|
February 27, 2021
REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer
Katrin M Sjoquist, David Espinoza, Linda Mileshkin, et al.
Asia-Pacific Journal of Clinical Oncology
|
December 1, 2010
A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas
Christos S Karapetis, Kerry A Cheong, Desmond Yip, et al.
Translational Oncology
|
February 28, 2024
Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial
Bonnita Werner, Katrin M Sjoquist, David Espinoza, et al.
The Journal of Clinical Investigation
|
September 17, 2024
Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance
Nima Sharifi, Robert Diaz, Hui-Ming Lin, et al.
BMC Cancer
|
August 31, 2018
Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours
Nicola J Lawrence, Howard Chan, Guy Toner, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 14, 2011
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]
Stephen J Clarke, Sonia Yip, Chris Brown, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|
October 5, 2019
Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial
Lauren R Olafson, Anna H Siddell, Kathryn M Field, et al.
BMC Cancer
|
August 20, 2021
AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer
Andrew Oar, Mark Lee, Hien Le, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 40) with videos related to
Sort By:
Page
of 4
The Oncologist
|
November 11, 2018
"As Long as You Ask": A Qualitative Study of Biobanking Consent-Oncology Patients' and Health Care Professionals' Attitudes, Motivations, and Experiences-the B-PPAE Study
Sonia Yip, Jennifer Fleming, Heather L Shepherd, et al.
British Journal of Cancer
|
August 6, 2019
Challenges of international oncology trial collaboration-a call to action
Monica Tang, Heikki Joensuu, Robert J Simes, et al.
Gynecologic Oncology
|
February 27, 2021
REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer
Katrin M Sjoquist, David Espinoza, Linda Mileshkin, et al.
Asia-Pacific Journal of Clinical Oncology
|
December 1, 2010
A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas
Christos S Karapetis, Kerry A Cheong, Desmond Yip, et al.
Translational Oncology
|
February 28, 2024
Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial
Bonnita Werner, Katrin M Sjoquist, David Espinoza, et al.
The Journal of Clinical Investigation
|
September 17, 2024
Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance
Nima Sharifi, Robert Diaz, Hui-Ming Lin, et al.
BMC Cancer
|
August 31, 2018
Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours
Nicola J Lawrence, Howard Chan, Guy Toner, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 14, 2011
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]
Stephen J Clarke, Sonia Yip, Chris Brown, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|
October 5, 2019
Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial
Lauren R Olafson, Anna H Siddell, Kathryn M Field, et al.
BMC Cancer
|
August 20, 2021
AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer
Andrew Oar, Mark Lee, Hien Le, et al.
Page
of 4